Answers are grounded in this paper and cite their sources.
Insufficient evidence exists on which antipsychotic is more efficacious for patients with treatment-resistant schizophrenia, and blinded RCTs-in contrast to unblinded, randomized effectiveness studies-provide little evidence of the superiority of clozapine compared with other second-generation antipsychotics. Future clozapine studies with high doses and patients with extremely treatment-refractory schizophrenia might be most promising to change the current evidence.
No takes yet. Share an insight, caveat, or question.
Samara et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: